T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Recruiting

Phase 3

T-DM1 & TucatinibT-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT04457596

Conditions

Anatomic Stage IA Breast Cancer AJCC V8

Anatomic Stage II Breast Cancer AJCC V8

Anatomic Stage IIA Breast Cancer AJCC V8

Anatomic Stage IIB Breast Cancer AJCC V8

Anatomic Stage III Breast Cancer AJCC V8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Trastuzumab Emtansine

Placebo Administration

Tucatinib

Questionnaire Administration

Quality-of-Life Assessment

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2025-03-25.